Adverse Events After BNT162b2 Do Not Differ for Cancer Patients
Among patients with cancer, pain at the injection site was less likely after dose 1 for those receiving active treatment
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.